TITLE

Sequenom acquires rights to Optherion's AMD genetic tests

PUB. DATE
February 2010
SOURCE
Medical Device Daily;2/10/2010, Vol. 14 Issue 27, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the exclusive worldwide licensing agreement reached by Sequenom with Optherion in February 2010. It states that the deal will allow the Sequenom Center for Molecular Medicine the rights to manufacture and market diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD). Other components of the deal are presented. Other topics discussed include the treatment goal of Sequenom and the benefits of the deal to both companies.
ACCESSION #
48043309

 

Related Articles

  • Optherion's Protein Replacement For AMD Nabs $37M Series A. Morrison, Trista // BioWorld Today;10/10/2007, Vol. 18 Issue 197, p1 

    The article reports on the amount raised by New Haven, Connecticut-based Optherion Inc. from a Series A financing. The company raised $37 million to advance its preclinical research with a new approach to diagnosing and treating age-related macular degeneration (AMD). The company is pursuing the...

  • Optherion wins protection from Canada for AMD diagnostics.  // Diagnostics & Imaging Week;5/7/2009, Vol. 12 Issue 18, p3 

    The article announces that the Canadian Patent Office has granted Optherion patents 2,363,503 and 2,407,715. The patents offer protection for diagnostic tests to identify the predisposition to age-related macular degeneration (AMD) by screening for genetic modificaitons in various genes such as...

  • NUVELO ASSIGNS PATENTS TO SEQUENOM.  // Biotech Business;Nov2003, Vol. 16 Issue 11, p4 

    Reports on the patent assignment and license agreement signed by Nuvelo Inc. and SEQUENOM Inc. as of November 2003.

  • TrovaGene stops Sequenom, regains transrenal tech rights.  // Medical Device Daily;8/11/2011, Vol. 15 Issue 150, p3 

    The article reports on the termination of a license agreement between TrovaGene and Sequenom in 2011.

  • Financings roundup.  // Medical Device Daily;10/10/2007, Vol. 11 Issue 194, p5 

    The article reports that Optherion, a company developing products to diagnose and treat dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system, has raised $37 million in start up financing. The company plans to develop...

  • Optherion's AMD Drug Nabs $37M Series A.  // Bioworld Week;10/15/2007, Vol. 15 Issue 42, p3 

    The article reports that Optherion Inc. in Connecticut has raised $37 million in a Series A round to further preclinical research with a new approach for the diagnosis and treatment of age-related macular degeneration (AMD). Optherion focuses on genetic mutations in Complement Factor H, which...

  • Pfizer licenses gene for possible AMD therapy.  // Ophthalmology Times;12/1/2006, Vol. 31 Issue 23, p8 

    The article reports on the acquisition of Pfizer Inc. of the worldwide license to a novel human gene with Quark Biotech Inc. in the U.S. Under the deal, the former will develop the gene called RTP-801, and molecules that modify it that could have the potential to treat neovascular age-related...

  • Global Age-Related Macular Degeneration Drug Pipeline Capsule -- 2011.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p32 

    The article presents the report of Fore Pharma entitled "Global Age-Related Macular Degeneration Drug Pipeline Capsule-2011." The report outlines the primary research and development (R&D) activities of the age-related macular degeneration drug market. It is also upgraded with the full coverage...

  • Sequenom signs European Licensing With LifeCodexx.  // Worldwide Biotech;Sep2011, Vol. 23 Issue 9, p3 

    The article reports on the licensing deal signed by biotechnology firms Sequenom Inc. and LifeCodexx AG for the commercialization of the European prenatal laboratory testing services. The deal will be Sequenom's first commercial partnership in the area of non-invasive prenatal diagnostics in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics